Ciclosporin is a promising treatment for autoimmune hepatitis, autoimmune cholangitis, and giant cell hepatitis.
In this study, physicians from Italy reviewed the records of 12 patients treated between 1987 and 2001.
Of these patients, 8 had autoimmune hepatitis, 2 had autoimmune cholangitis and 2 had giant cell hepatitis.
The indication for ciclosporin therapy was treatment failure in 4 patients and contraindications to steroids in 8.
Ciclosporin was administered in 5 untreated cases and in 7 patients during relapse.
The mean duration of ciclosporin administration was 35.6 months, and median follow-up was 6.5 years.
|There was no treatment withdrawal due to side-effects.|
|Alimentary Pharmacology and Therapeutics|
The team found that all patients achieved complete remission in a median of 4.5 weeks.
There was also no treatment withdrawal due to side-effects.
The physicians found that 3 patients required a combination of ciclosporin with conventional treatment due to severe liver function impairment.
Overall, the team determined that tolerance to ciclosporin was excellent. There was a 20% transient elevation of serum creatinine in 1 patient, gingival hypertrophy in 2, and moderate hypertrichosis in 2.
Dr Sciveres's team concluded, "Ciclosporin may be considered as a safe treatment for all autoimmune liver diseases and as an effective alternative for front-line therapy".